ArticleProceedings of the National Academy of Sciences of the United States of America2002
Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 112 citations in OpenAlex.
- Molecular cloning of a monkeypox virus clade IIb genome and construction of an attenuated mutant for basic and translational research.Emerging microbes & infections · 2026Article
- Viral genome editing methods and applications in the CRISPR era.Journal of virology · 2026Review
- Development of a replication-defective mpox virus platform for fundamental and therapeutic research.Nature communications · 2025Article
- Vaccinia Virus-A Swiss Army Knife Against Cancer.Cancers · 2025Review
- Article
- The Potential of Disabled Infectious Single Cycle (DISC) Virus Platforms for Next Generation African Swine Fever Vaccine Development.Transboundary and emerging diseases · 2025Review
- Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development.Frontiers in microbiology · 2025Article
- Mpox Virus and its ocular surface manifestations.The ocular surface · 2024Review
- Article
- Post-genomic era in agriculture and veterinary science: successful and proposed application of genetic targeting technologies.Frontiers in veterinary science · 2023Review
- Efficient production of protein complexes in mammalian cells using a poxvirus vector.PloS one · 2022Article
- Extracellular Vesicles and Their Use as Vehicles of Immunogens.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Concurrent expression ofMolecular therapy oncolytics · 2021Article
- MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage.Journal of molecular biology · 2021Article
- Review
- Budding yeast as a factory to engineer partial and complete microbial genomes.Current opinion in systems biology · 2020Review
- X69R Is a Non-Essential Gene That, When Deleted from African Swine Fever, Does Not Affect Virulence in Swine.Viruses · 2020Article
- Smallpox in the Post-Eradication Era.Viruses · 2020Review
- Synthetic horsepox viruses and the continuing debate about dual use research.PLoS pathogens · 2018Article
- Synthetic viruses-Anything new?PLoS pathogens · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The ability to manipulate the vaccinia virus (VAC) genome, as a plasmid in bacteria, would greatly facilitate genetic studies and provide a powerful alternative method of making recombinant viruses. VAC, like other poxviruses, has a linear, double-stranded DNA genome with covalently closed hairpin ends that are resolved from transient head-to-head and tail-to-tail concatemers during replication in the cytoplasm of infected cells. Our strategy to construct a nearly 200,000-bp VAC-bacterial artificial chromosome (BAC) was based on circularization of head-to-tail concatemers of VAC DNA. Cells were infected with a recombinant VAC containing inserted sequences for plasmid replication and maintenance in Escherichia coli; DNA concatemer resolution was inhibited leading to formation and accumulation of head-to-tail concatemers, in addition to the usual head-to-head and tail-to-tail forms; the concatemers were circularized by homologous or Cre-loxP-mediated recombination; and E. coli were transformed with DNA from the infected cell lysates. Stable plasmids containing the entire VAC genome, with an intact concatemer junction sequence, were identified. Rescue of infectious VAC was consistently achieved by transfecting the VAC-BAC plasmids into mammalian cells that were infected with a helper nonreplicating fowlpox virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.